AlphAIAlphAI — Financial news for AI agents
investing.comOCT 22 min read$NKTR

H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data

H.C. Wainwright reiterated a Buy rating and $185 price target on Nektar Therapeutics (NKTR) after positive alopecia data. NKTR shares fell 22.4% on Oct 1, despite analysts' bullish consensus. NKTR reported a smaller-than-expected Q2 2026 loss but missed revenue expectations. NKTR won a $90M verdict against Eli Lilly.

Original reporting
investing.com
Published Oct 2, 2026, 11:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$NKTR
Bearish
high confidence
Mentioned
$NKTR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NKTRBearishMed
01

Why it matters

The data release triggered a sharp share decline despite an analyst reaffirming a buy rating, indicating market skepticism about the durability of responses and the commercial potential of the alopecia program.

02

Market read

The mixed trial results and legal award create short‑term downside risk for NKTR, while the buy rating suggests some upside potential if later data improve.

03

What to watch

Potential future partnership opportunities for the alopecia asset and the company's cash runway through 2028.

Relevance 8/10Novelty 8/10Timing: today

Background

Nektar Therapeutics (NASDAQ: NKTR) is a clinical‑stage biotech focused on immuno‑oncology and dermatology. The REZOLVE‑AA Phase 2b trial data were presented at a major dermatology congress, and the company also reported a favorable court verdict against Eli Lilly.

Company-level read

Ticker impact

$NKTRBearishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating and $185 price target after Nektar Therapeutics presented Phase 2b alopecia trial data and disclosed a $90 million jury verdict against Eli Lilly.

Expected impact

likely continued pressure as investors digest mixed trial results and the sizable legal award

Evidence & confidence

The trial data showed modest response durability and the stock already dropped sharply; no new positive catalyst was introduced.

Market effects

Sector

Biotech sector may see heightened scrutiny of early‑stage dermatology programs after mixed efficacy signals.

Regional

U.S. biotech stocks could face short‑term volatility in early‑trade as investors reassess trial pipelines.

Global

Limited to investors tracking niche biotech and dermatology therapeutics worldwide.

Counterpoint

What could challenge this read

The $90 M legal win could offset trial concerns, offering a floor valuation for NKTR.

Key entities

  • company
    Nektar Therapeutics

    Biotech firm presenting Phase 2b alopecia data and receiving a $90 M jury award.

  • analyst_firm
    H.C. Wainwright

    Reiterated a Buy rating and $185 price target for NKTR.

  • company
    Eli Lilly and Company

    Defendant in the $90 M jury verdict case.

Read at source← All news

Related articles

OCT 8
$NKTRMed

Raymond James initiates Nektar stock coverage with Market Perform

Raymond James initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating, citing its focus on autoimmune therapies and cash burn. The stock is down 46% over six months, with a market cap of $1.39 billion. Nektar reported a smaller-than-expected Q2 2026 loss but missed revenue forecasts. The company won a $90 million verdict against Eli Lilly and received a Buy rating with a $185 price target from H.C. Wainwright.

investing.com2 min
OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min